Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 3/20 | 0.45 |
| ▸ | CCKBR | P32239 | 3/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.36 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.36 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5615867 | 1.00 | GHSR (0.45) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| SCHEMBL2579166 | 1.00 | GHSR (0.45) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| Hydrochloric Acid SCHEMBL8313866 | 0.99 | GHSR (0.44) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| SCHEMBL2575425 | 0.93 | GHSR (0.46) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| SCHEMBL2579092 | 0.93 | GHSR (0.46) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| SCHEMBL5615551 | 0.93 | GHSR (0.46) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| SCHEMBL2577149 | 0.93 | GHSR (0.46) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| SCHEMBL2575426 | 0.93 | GHSR (0.46) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| Hydrochloric Acid SCHEMBL8315714 | 0.92 | GHSR (0.45) | GHSRCCKBRHSD11B1HSD11B2TACR1 | |
| Hydrochloric Acid SCHEMBL8315713 | 0.92 | GHSR (0.45) | GHSRCCKBRHSD11B1HSD11B2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0662481-B1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | claimed |
| US-5578593-A | RELEASING GROWTH HORMONES FOR ANIMALS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | claimed |
| EP-0662481-A1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO. INC. (US) | 1995-07-12 | — | — | EP | claimed |
| EP-2389941-A1 | Growth-hormone secretagogues | Elixir Pharmaceuticals, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20080261873-A1 | Growth-Hormone Secretagogues | ELIXIR PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-0662481-B1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5578593-A | RELEASING GROWTH HORMONES FOR ANIMALS | MERCK & CO., INC. (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0662481-A1 | Spiro piperidines and homologs promote release of growth hormone | MERCK & CO. INC. (US) | 1995-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261873-A1 | Growth-Hormone Secretagogues | GHSR, GHRHR, GIPR | GHSR 1/4885CCKBR 8/4885HSD11B1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.